Experimental drug shows promise for tough bone cancer

NCT ID NCT03514407

First seen Oct 31, 2025 · Last updated Apr 25, 2026 · Updated 22 times

Summary

This study tested a new drug called INCB059872 in people with Ewing sarcoma that had returned or stopped responding to standard treatments. The goal was to see if the drug is safe and if it can shrink tumors. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, 08035, Spain

  • Istituto Ortopedico Rizzoli

    Bologna, 40136, Italy

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic Jacksonville - PPDS

    Jacksonville, Florida, 32224, United States

  • Ospedale Pediatrico Bambino Gesu IRCCS

    Rome, 00146, Italy

  • Policlinico Sant'orsola-Malpighi

    Bologna, 40138, Italy

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • UCLA Jonsson Comprehensive Cancer

    Los Angeles, California, 90095, United States

Conditions

Explore the condition pages connected to this study.